Three homegrown treatments for the coronavirus are expected to receive approval as early as the first half of this year.
The Ministry of Food and Drug Safety granted conditional approval for Celltrion to market its Covid-19 treatment, but only to patients with mild to moderate symptoms.
Daewoong Pharmaceutical’s Foister tablets received a nod from the government for Phase 3 clinical trials as a preventive drug, the company said Monday.
Democratic Party Chairman Lee Nak-yon said Tuesday Korea may have vaccination and treatment programs for Covid-19 running as early as next month. “With any luck, Korea may be able to have a well-running and complete system of testing...
GC Pharma completed injections for Phase 2 clinical trials of its Covid-19 treatment candidate in late December, the company confirmed Wednesday.
The cluster outbreaks at residential treatment centers had been long foreseen. Virus infection and seriously-ill senior patients is a lethal mix. Caring for them in the same facility would require highly delicate quarantine...
Celltrion submitted an application to obtain a conditional use permit for its Covid-19 treatment candidate CT-P59 on Tuesday. With the Phase 2 trials finished, it will also prepare to obtain emergency use authorization in the U.S. and Europe as well.
Local governments are stepping up to achieve carbon neutrality, using ideas from food waste-derived biogas to building new public rental housing equipped with solar panels.
Daewoong Pharmaceutical will receive government funding to establish production facilities for its Covid-19 treatment candidate. The company will receive a maximum 19 trillion won ($17.2 billion) from the Ministry of Health and Welfare by until 2021.
A Celltrion Covid-19 treatment candidate was approved for individual use on patients who have experienced little benefit from authorized treatments.